Vorinostat (SAHA), the inhibitor of HDAC1, has been approved by the FDA as an effective drug for the treatment of cutaneous T cell lymphoma [35]. The gene discussed is HDAC1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.